Skip to Content


Class: Antineoplastic Agents
VA Class: AN200
Molecular Formula: C15H18N4O5
CAS Number: 50-07-7
Brands: Mutamycin

Medically reviewed by Last updated on June 30, 2020.


    Experience of Supervising Clinician
  • Administer only under the supervision of a qualified clinician experienced in therapy with chemotherapeutic agents.100 d Use only when adequate treatment facilities for appropriate management of therapy and complications are available.100 d (See Toxicity under Cautions.)

  • Risk of dose-limiting, cumulative myelosuppression and potentially life-threatening secondary infections (e.g., septicemia).100 c d (See Hematologic Effects under Cautions.)

    Hemolytic Uremic Syndrome
  • Undefined risk of severe and often fatal syndrome consisting principally of microangiopathic hemolytic anemia (hematocrit ≤25%), thrombocytopenia (platelet count ≤100,000/mm3), and irreversible renal failure (Scr ≥1.6 mg/dL).100 101 102 103 104 105 106 107 108 d (See Hemolytic Uremic Syndrome under Cautions.)

  • May occur at any time during therapy (with or without other antineoplastic agents); however, most cases occur at mitomycin doses ≥60 mg.100 d Blood transfusion may exacerbate the symptoms associated with this syndrome.100 d


Antineoplastic agent; an antibiotic produced by Streptomyces caespitosus.100 c d

Uses for Mitomycin

Adenocarcinoma of Stomach and Pancreas

Component of combination chemotherapeutic regimens for treatment of disseminated adenocarcinoma of the stomach or pancreas and as palliative treatment of these tumors when other treatment modalities are ineffective.100 121 d

Response rates generally low (10–17%) and of short duration.c

Not recommended for use as single-agent, primary therapy or as a replacement for appropriate surgery and/or radiation therapy.100 d

Anal Cancer

A preferred regimen, in combination with fluorouracil, for primary treatment of anal cancer.121

Bladder Cancer

Has been used for intravesical treatment of residual tumor and/or as adjuvant therapy for prophylaxis of superficial bladder cancer.113 115 120 121 130 131 138

Causes regression of existing papillary tumor and reduces the rate of short-term tumor recurrence but has no effect on disease progression or overall survival.119 123 124 129 139

Cervical Cancer

Has been used in cisplatin-containing combination chemotherapy regimens (e.g., bleomycin, cisplatin, mitomycin, and vincristine) for treatment of metastatic or recurrent cervical cancer.132 135

Other agents generally preferred for treatment of advanced cervical cancer.136 137

Non-small Cell Lung Cancer

Has been used for treatment of non-small cell lung cancer in combination with cisplatin and vinblastine (MVP) 121 146 149 or ifosfamide with mesna (MIC).121 150

Other chemotherapeutic regimens (e.g., cisplatin with paclitaxel, vinorelbine, or gemcitabine) currently preferred for treatment of advanced non-small cell lung cancer.121 146

Malignant Mesothelioma

Has been used for treatment of malignant mesothelioma.121

Head and Neck Carcinoma

Has been used as an adjunct to radiation therapy for treatment of squamous cell carcinoma of head and neck.147

Breast Cancer

Has shown activity for treatment of metastatic breast cancer.148

Mitomycin Dosage and Administration


  • Consult specialized references for procedures for proper handling and disposal of antineoplastic drugs.100 d

  • Administer mitomycin only after complete hematologic recovery from any previous chemotherapy occurs.100


Administer IV.100 c d

Has been administered intravesically; notan approved route of administration.100 115 120 121 130 131 138 d

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Administer via a functioning IV catheter;100 c d some clinicians recommend administering the drug through tubing of an IV infusion.c Use care to avoid extravasation.100 d (See Mucocutaneous Effects under Cautions.)


Reconstitute vial containing 5, 20, or 40 mg of mitomycin with 10, 40, or 80 mL of sterile water for injection, respectively, to provide a solution containing approximately 0.5 mg/mL.100 c d

Shake vial to dissolve.100 c d If the powder does not dissolve immediately, allow the vial to stand at room temperature until complete dissolution occurs.100 c d


Consult published protocols for dosages of mitomycin and other chemotherapeutic agents and the method and sequence of administration.c

Individualize dosage based on clinical and hematologic response and tolerance of the patient and whether or not other myelosuppressive therapy also is being used.100 c d

Reevaluate patients after each course of therapy and adjust dosages as needed.100 d


Adenocarcinoma of Stomach and Pancreas

Initially, 20 mg/m2 as a single IV dose every 6–8 weeks.100 d Doses >20 mg/m2 are not more effective and increase risk of toxicity.100 d

Adjust subsequent dosages according to the hematologic response to the previous dose.100 d (See Table 1.)Do not administer repeat dosage until leukocyte count has returned to 4000/mm3 and platelet count to 100,000/mm3.100 d

Table 1: Dosage Modification for Myelosuppression Based on Nadir After Prior Dose100d

Leukocytes (cells/ mm3)

Platelets (cells/ mm3)

Percentage of Prior Dose to Be Given













If disease continues to progress after 2 courses of therapy, discontinue the drug since likelihood of response is minimal.100 d

Bladder Cancer†
Treatment of Superficial Bladder Cancer†

Usual dosage: 20–60 mg once weekly,115 116 118 120 125 126 127 128 administered as soon as possible following transurethral resection (TUR).117 128 For patients treated within 6–24 hours following TUR, a 6-month course of therapy generally is sufficient; however, for patients in whom intravesical therapy is instituted ≥24 hours following surgery, a 12-month course usually is recommended.117 128 No additional benefit demonstrated for continued maintenance therapy.115 116 120 124 128 131

Special Populations

Hepatic Impairment

No special dosage recommendations at this time.100 d

Renal Impairment

Do not administer if Scr >1.7 mg/dL.100 d (See Renal Effects under Cautions.)

Geriatric Patients

No special dosage recommendations at this time.100 d

Cautions for Mitomycin


  • Thrombocytopenia, coagulation disorder, or an increase in bleeding tendency due to other causes.100 c d (See Hematologic Effects under Cautions.)

  • Known hypersensitivity or idiosyncratic reaction to mitomycin.100 c d




Highly toxic drug with a low therapeutic index.c Administer only under the supervision of a qualified clinician experienced in use of cancer chemotherapeutic agents.100 c d (See Boxed Warning and also see Hematologic Effects, Renal Effects, Hemolytic Uremic Syndrome, and Respiratory Effects under Cautions.)

Hematologic Effects

High incidence of cumulative myelosuppression, principally thrombocytopenia and leukopenia.100 c d (See Boxed Warning.) Not related to total dose; however, occurs more frequently with certain dosage regimens.c

Monitor hematologic status (platelet count, leukocyte count, differential, PT, bleeding time, and hemoglobin) repeatedly during therapy and for ≥8 weeks afterwards.100 c d Withhold therapy if leukocyte count <4000/mm3, platelet count <100,000/mm3, or if a progressive decline in either occurs.100 d (See Table 1.)

Myelosuppression may occur anytime within 8 weeks after initiation of therapy; may be severe (e.g., platelet count ≤50,000/mm3, leukocyte count ≤2000/mm3).100 c d Nadir during 4–6 weeks of therapy.c Recovery usually occurs ≤10 weeks after therapy discontinued; however, about 25% of cases may be irreversible.100 d

Hemorrhagic Complications

Bleeding due to thrombocytopenia may occur.c Platelet transfusions may be needed.c

Infectious Complications

Life-threatening infections secondary to leukopenia (e.g., septicemia) reported.100 c d

Renal Effects

Renal toxicity (e.g., increased BUN and/or Scr) reported.100 c d Possibly related to total dose administered (e.g., low risk at cumulative doses <50 mg/m2; substantially increases with higher cumulative doses);101 108 however, not clearly established.100 d

Monitor renal function.100 Do not administer if Scr >1.7 mg/dL.100 d

Renal failure also may occur as a component of hemolytic uremic syndrome.100 101 102 103 104 105 106 107 108 (See Hemolytic Uremic Syndrome under Cautions and also see Boxed Warning.)

Fetal/Neonatal Morbidity

May cause fetal harm; teratogenicity demonstrated in animals.100 d

Safe use of mitomycin in pregnant women not established.100 d

Major Toxicities

Hemolytic Uremic Syndrome

Hemolytic uremic syndrome, a severe and often fatal syndrome of microangiopathic hemolytic anemia (hematocrit ≤25%), thrombocytopenia (platelet count ≤100,000/mm3), and irreversible renal failure (Scr ≥1.6 mg/dL), reported.100 101 102 103 104 105 106 107 108 d Pulmonary edema also may be a component; may be a particularly grave prognostic factor.100 104 d Other complications include neurologic abnormalities and hypertension.100 d (See Boxed Warning.)

Syndrome can vary from a chronic course with mild anemia and slowly progressive renal impairment to a fulminant course with severe anemia, rapid deterioration of renal function, and death.101 102 103 104 105 106 107 108

May occur at any time during therapy (with or without other antineoplastic agents); however, most cases occur at doses ≥60 mg.100 d Blood transfusion may exacerbate symptoms.100 d

Closely monitor patients receiving mitomycin doses ≥60 mg for unexplained anemia with fragmented cells on peripheral blood smear, thrombocytopenia, and decreased renal function.100 d

Optimum management of syndrome not established; use of systemic corticosteroids, plasma exchange, plasmapheresis, and/or IV vincristine beneficial in some patients, and early treatment may be preferred.103 104 105 106 107 108 (See Specific Drugs under Interactions.) Manufacturer states that therapy for syndrome is investigational.100 d

General Precautions

Mucocutaneous Effects

Extremely irritating to tissues.c Mucocutaneous toxicity (e.g., mouth ulcers, alopecia, desquamation, pruritus) may occur; appears related to the total dose given.c d

Extravasation possible; may cause severe cellulitis, ulceration, and tissue sloughing.100 d May occur with or without symptoms (e.g., stinging or burning during administration) and even when blood returns well during initial aspiration of infusion needle.100 d (See IV Administration under Dosage and Administration.)

Possible pain on injection, induration, thrombophlebitis, and paresthesia.c Delayed erythema and/or ulceration at or distant from the injection site possible weeks to months after administration despite the lack of apparent evidence of extravasation.100 d

Respiratory Effects

Possibly severe or life-threatening acute bronchospasm and/or dyspnea may occur a few minutes to several hours after administration of a vinca alkaloid (e.g., vinblastine) in patients who have been previously or simultaneously treated with mitomycin.100 c d Bronchodilators, corticosteroids, and/or oxygen may produce symptomatic relief.100 d

ARDS reported in some patients receiving mitomycin in combination with other antineoplastic agents and maintained at fraction of inspired oxygen (FIO2) concentrations >50% perioperatively.100 d Use only enough oxygen to provide adequate arterial saturation.100 d

Monitor patients for evidence of pulmonary toxicity (e.g., dyspnea with a nonproductive cough, radiographic evidence of pulmonary infiltrates) and for changes in fluid balance; avoid overhydration.100 d If pulmonary toxicity develops, discontinue therapy if other etiologies can be excluded.100 d

Intravesical Instillation

Bladder fibrosis/contraction reported;100 d may require cystectomy.100 d

Asymptomatic ulcers at the site of resected carcinoma of the bladder109 110 111 and calcification of bladder wall reported.112

Possible local irritation (i.e., cystitis); local toxicity increases with the number and frequency of instillations and with the dose administered.115

GI Effects

Nausea and vomiting may occur within 1–2 hours of IV administration.100 c d Vomiting usually subsides rapidly but nausea can continue for 2–3 days.c

Specific Populations


Category C.100 d (See Fetal/Neonatal Morbidity under Cautions.)


Not known whether mitomycin is distributed into milk.100 d Discontinue nursing during mitomycin therapy.100 d

Pediatric Use

Safety and efficacy not established.100 d

Renal Impairment

Do not use if Scr >1.7 mg/dL.100 d Monitor renal function prior to and periodically during therapy.100 d (See Renal Effects under Cautions.)

Common Adverse Effects

IV administration: Myelosuppression, nausea, vomiting, anorexia, stomatitis, fever, alopecia.100 d

Intravesical instillation: Local irritation (i.e., cystitis).115

Interactions for Mitomycin

Specific Drugs




Antineoplastic agents

Risk of acute pulmonary reactions following administration of vinca alkaloids (e.g., vinblastine, vincristine, vinorelbine) in patients previously or concomitantly treated with mitomycin100 d (see Respiratory Effects under Cautions)

Risk of ARDS in patients receiving mitomycin in combination with other chemotherapeutic agents and oxygen therapy100 c d (see Respiratory Effects under Cautions)

Bronchodilators, corticosteroids, and/or oxygen may produce symptomatic relief from acute bronchospasm and/or dyspnea100 d

Use only enough oxygen to provide adequate arterial saturation during ARDS100 d

Myelosuppressive agents

Adjust dosages accordingly when used concomitantly100 d

Mitomycin Pharmacokinetics



Rapidly distributed into tissues.c

In animals, highest concentrations found in the kidneys, followed by muscles, eyes, lungs, intestines, and stomach; not detectable in the liver, spleen, or brain (rapidly inactivate mitomycin).c

Higher concentrations of the drug are generally present in cancer tissues than in normal tissues.c

Not known whether mitomycin is distributed into milk.100 d



Rapidly inactivated in microsomal fraction of the liver and also in the kidneys, spleen, brain, and heart, which contain high concentrations of enzymes capable of metabolizing the drug.100 c

Elimination Route

Excreted principally in urine (about 10% as active drug) and to a small extent in bile.100 c d

Rate of clearance inversely proportional to the maximum serum concentration because of saturation of degradative pathways.100 d


For 30-mg IV injection: 17 minutes.100 d




Powder for Injection

15–30°C.c d Protect from lightc and avoid excessive heat (>40°C).100 c d Commercially available mitomycin powder is stable for at least 4 years at room temperature.c

Reconstituted solutions are stable for 7 days at room temperature and for 14 days at 2–8°C.100 c d Protect from light.d


For information on systemic interactions resulting from concomitant use, see Interactions.


Solution Compatibility100 HID

Solutions of mitomycin diluted to a concentration of 20–40 mcg/mL are stable at room temperature for 3 hours in 5% dextrose injection, 12 hours in 0.9% sodium chloride, and 24 hours in sodium lactate injection.100 c d


Ringer’s injection, lactated

Sodium chloride 0.4 or 0.6%


Dextrose 3.3% in sodium chloride 0.3%


Dextrose 5% in water

Sodium chloride 0.9%

Sodium lactate 1/6 M

Drug Compatibility

The combination of mitomycin 5–15 mg and heparin sodium 1000–10,000 units in 30 mL of 0.9% sodium chloride injection is stable for 48 hours at room temperature.100 d

Admixture CompatibilityHID


Dexamethasone sodium phosphate

Hydrocortisone sodium succinate


Bleomycin sulfate


Heparin sodium

Y-Site CompatibilityHID



Bleomycin sulfate

Caspofungin acetate



Doxorubicin HCl




Granisetron HCl

Heparin sodium

Leucovorin calcium

Melphalan HCl

Methotrexate sodium

Metoclopramide HCl

Ondansetron HCl



Vinblastine sulfate

Vincristine sulfate



Etoposide phosphate


Gemcitabine HCl

Piperacillin sodium–tazobactam sodium


Topotecan HCl

Vinorelbine tartrate

Actions and Spectrum

  • Mechanism of antineoplastic activity similar to that of other alkylating agents.c

  • Enzymatic reduction of mitomycin within susceptible cells may be necessary for antineoplastic activity.c

  • Activated mitomycin appears to selectively inhibit the synthesis of deoxyribonucleic acid (DNA) by causing cross-linking of DNA.100 c d In high concentrations, may also inhibit RNA and protein synthesis.100 d

  • Active against gram-positive bacteria and some viruses; however cytotoxicity precludes use as an anti-infective agent.c

Advice to Patients

  • Importance of advising patients of potentially life-threatening hematologic (e.g., myelosuppression), respiratory, and renal toxicities associated with mitomycin therapy.100 c d

  • Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.100 d

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses (e.g., bleeding disorders).100 d

  • Importance of informing patients of other important precautionary information.100 d (See Cautions.)


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name



Dosage Forms


Brand Names



For injection

5 mg*

Mitomycin for Injection


Bristol-Myers Squibb

20 mg*

Mitomycin for Injection


Bristol-Myers Squibb

40 mg

Mitomycin for Injection


Bristol-Myers Squibb

AHFS DI Essentials™. © Copyright 2021, Selected Revisions July 10, 2013. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.


Only references cited for selected revisions after 1984 are available electronically.

100. Bristol-Myers Squibb. Mutamycin (mitomycin for injection) prescribing information. Princeton, NJ; 2000 Jan.

101. Valavaara R, Nordman E. Renal complications of mitomycin C therapy with special reference to the total dose. Cancer. 1985; 55:47-50.

102. Pavy MD, Wiley EL, Abeloff MD. Hemolytic-uremic syndrome associated with mitomycin therapy. Cancer Treat Rep. 1982; 66:457-61.

103. Rabadi SJ, Khandekar JD, Miller HJ. Mitomycin-induced hemolytic uremic syndrome: case presentation and review of literature. Cancer Treat Rep. 1982; 66:1244-7.

104. Sheldon R, Slaughter D. A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. Cancer. 1986; 58:1428-36.

105. Price TM, Murgo AJ, Keveney JJ et al. Renal failure and hemolytic anemia associated with mitomycin C: a case report. Cancer. 1985; 55:51-6.

106. Lyman NW, Michaelson R, Viscuso RL et al. Mitomycin-induced hemolytic-uremic syndrome: successful treatment with corticosteroids and intense plasma exchange. Arch Intern Med. 1983; 143:1617-8.

107. Grem JL, Merritt JA, Carbone PP. Treatment of mitomycin-associated microangiopathic hemolytic anemia with vincristine. Arch Intern Med. 1986; 146:566-8.

108. Hamner RW, Verani R, Weinman EJ. Mitomycin-associated renal failure: case report and review. Arch Intern Med. 1983; 143:803-7.

109. Richards B, Tolley D. Benign ulcers after bladder instillation of mitomycin C. Lancet. 1986; 1:45.

110. Hetherington JW, Whelan P. Persistent ulcers after bladder instillation of mitomycin C. Lancet. 1986; 1:324.

111. Tolley DA, Hargreave TB, Smith PH et al. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). BMJ. 1988; 296:1759-61.

112. Alter AJ, Malek GH. Bladder wall calcification after topical mitomycin C. J Urol. 1987; 138:1239-40.

113. Bladder cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2008 May 16.

114. Scher HI, Shipley WU, Herr HW. Cancer of the bladder. In: DeVita VT Jr, Hellman S, Rosenberg SA eds. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven Publishers; 1997:1300-22.

115. Witjes JA. Current recommendations for the management of bladder cancer: drug therapy. Drugs. 1997; 53:404-14.

116. Raghaven D, Huben R. Management of bladder cancer. Curr Prob Cancer. 1995; 19:1-64.

117. Kurth KH. Diagnosis and treatment of superficial transitional cell carcinoma of the bladder: facts and perspectives. Eur Urol. 1997; 31(Suppl 1):10-9.

118. Boccardo F, Cannata D, Rubagotti A et al. Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. J Clin Oncol. 1994; 12:7-13.

119. Lamm DL, Griffith JG. Intravesical therapy: does it affect the natural history of superficial bladder cancer? Semin Urol. 1992; 10:39-44.

120. Tolley DA, Parmar MKB, Grigor KM et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of followup. J Urol. 1996; 155:1233-8.

121. Anon. Drugs of choice for cancer. Treat Guidel Med Lett. 2003; 1:41-52.

122. Bouffioux C. Intravesical adjuvant treatment in superficial bladder cancer: a review of the question after 15 years of experience with the EORTC GU group. Scand J Urol Nephrol Suppl. 1991; 138:167-77.

123. Nseyo UO, Lamm DL. Therapy of superficial bladder cancer. Semin Oncol. 1996; 23:598-604.

124. Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am. 1992; 19:573-80.

125. Lundholm C, Norlén BJ, Ekman P et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol. 1996; 156:372-6.

126. Witjes JA, Meijden APM, Witjes WPJ et al. A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Eur J Cancer. 1993; 29A:1672-6.

127. Krege S, Giani G, Meyer R et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. J Urol. 1996; 156:962-6.

128. Bouffioux C, Kurth KH, Bono A et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. J Urol. 1995; 153:934-41.

129. Pawinski A, Sylvester R, Kurth KH et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol. 1996; 156:1934-41.

130. Bouffioux C, van der Meijden A, Kurth KH et al. Objective response of superficial bladder tumors to intravesical treatment (including review of response of marker lesions). Prog Clin Biol Res. 1992; 378:29-42.

131. Akaza H, Isaka S, Koiso K et al. Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Cancer Chemother Pharmacol. 1987; 20(Suppl):S91-6.

132. Shimizu Y, Akiyama F, Umezawa S et al. Combination of consecutive low-dose cisplatin with bleomycin, vincristine, and mitomycin for recurrent cervical carcinoma. J Clin Oncol. 1998; 16:1869-78.

133. Omura GA, Blessing JA, Vaccarello L et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1997; 15:165-71.

134. Kumar L, Pokharel YH, Kumar S et al. Single agent versus combination chemotherapy in recurrent cervical cancer. J Obstet Gynaecol Res. 1998; 24:401-9.

135. Alberts DS, Kronmal R, Baker LH et al. Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study. J Clin Oncol. 1987; 5:1791-5.

136. Thigpen T, Blessing JA, Gallup DG et al. Phase II trial of mitomycin-C in squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1995; 57:376-9.

137. Reviewers’ comments (personal observations) on cervical cancer.

138. Heney NM, Koontz WW, Barton B et al. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study. J Urol. 1988; 140:1390-3.

139. Smith JA Jr, Labasky RF, Cockett ATK et al. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol. 1999; 162:1697-701.

140. Herr HW, Schwalb DM, Zhang ZF et al. Intravesical Bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol. 1995; 13:1404-8.

141. De Jager R, Guinan P, Lamm D et al. Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette-Guerin: overview analysis of six phase II clinical trials. Urology. 1991; 38:507-13.

142. Sarosdy MF, Lamm DL. Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol. 1989; 142:719-22.

143. Malmstrom PU, Wijkstrom H, Lundholm C et al. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol. 1999; 161:1124-7.

144. Ali-el-Dein B, Nabeeh A, el-Baz M et al. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol. 1997; 79:731-5.

145. Okamura K, Kinukawa T, Tsumura Y et al. A randomized study of short- versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncology Group. Eur Urol. 1998; 33:285-9.

146. Non-small cell lung cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2008 May 22.

147. Haffty BG, Son YH, Papac R et al. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale Mitomycin Randomized Trials. J Clin Oncol. 1997; 15:268-76.

148. Breast cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2008 Apr 3.

149. Veeder MH, Jett JR, Su JQ et al. A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma. Cancer. 1992; 70:2281-7.

150. Crino L, Scagliotti GV, Ricci S et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol. 1999; 17:3522-30.

152. UKCCCR Anal Cancer Trial Working Party, UK Co-ordinating Committee on Cancer Research. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet. 1996; 348:1049-54.

153. Bartelink H, Roelofsen F, Eschwege F et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997; 15:2040-9.

154. Flam M, John M, Pajak TF et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996; 14:2527-39.

155. Ajani JA, Winter KA, Gunderson LL et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008; 299:1914-21.

HID. Trissel LA. Handbook on injectable drugs. 17th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2013:807-812.

c. AHFS drug information 2009. McEvoy GK, ed. Mitomycin. Bethesda, MD: American Society of Health-System Pharmacists; 2009:1174–6.

d. Bedford Laboratories. Mitomycin for injection prescribing information. Bedford, OH; 2000 Jun.